×

HEPREGEN LAUNCHES FIRST MONKEY HEPATOPACTM ASSAY KITS AT ANNUAL USER GROUP MEETING

desc

CAMBRIDGE, MASS., Oct. 29, 2013 (GLOBE NEWSWIRE) --

Today, at the Company's annual User Group Meeting, Hepregen Corporation, leader in the development of next generation HepatoPacTM and HepatoMuneTM cell-based assay products, announced the commercial launch of the Company's first application-oriented, monkey HepatoPacTM kits, designed specifically for use in metabolite identification and profiling. The kits contain one or more standard 24-well tissue culture plates containing micro-patterned monkey liver cells co-cultured with stromal cells. The liver cells (hepatocytes) on these plates remain fully functional for up to 35 days. Each of the kits provides customers with a plug-in-ready product that can be used to evaluate metabolite production in monkey liver cells.

Dr. Vincent Zurawski, Hepregen's chief executive officer stated, "This new monkey HepatoPacTM kit adds a fifth product for metabolite identification and profiling to Hepregen's growing application-directed product line. This monkey kit complements the recently introduced human, rat, human triple-donor and rat-human HepatoPacTM kits for metabolite identification and profiling."

About Hepregen Corporation

Hepregen Corporation is the undisputed leader in innovating unique and proprietary bioengineered micro-liver platforms for use in environmental testing, preventive care, and pharmaceutical, biotherapeutic and diagnostic product development. The Company's micro-liver HepatoPacTM and HepatoMuneTM cell-based assays are driving a paradigm shift in drug development. The utility of Hepregen's human, rat, monkey, dog, and multi-species/multi-donor HepatoPacTM and HepatoMuneTM products has been validated in collaboration with investigators at several well-known pharmaceutical companies. Additionally, new applications for these products are being tested by Hepregen, its pharmaceutical company customers, and its academic and business partners. Hepregen was founded and capitalized by Battelle Ventures with technology licensed from the Massachusetts Institute of Technology. The technology was developed by Professor Sangeeta Bhatia, who is a world renowned expert and leader in liver bioengineering for life science and therapeutic applications.



A photo accompanying this release is available at:
http://www.globenewswire.com/newsroom/prs/?pkgid=21886

CONTACT: Hepregen Corporation Katherine Sydney Cook Tel: 1-781-391-0205 x108 Email: ksydneycook@hepregen.com www.hepregen.comSource: Hepregen